A Phase 3, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

Trial Profile

A Phase 3, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms ENDEAR
  • Sponsors Medivation
  • Most Recent Events

    • 17 May 2017 According to an Astellas Pharma media release, based on the enzalutamide data from the Phase-2 HER2+ and ER/PR+ breast cancer studies, the company decided not conduct Phase 3 studies at this time.
    • 17 May 2017 Status changed from recruiting to withdrawn prior to enrolment, according to an Astellas Pharma media release.
    • 07 Oct 2016 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top